有人受伤较重或突发急症需要去医院？——打"120"叫救护车。这和报警打"110"、发现火灾打"119"一 样，是生活常识。 近年来，我国多地急救网络建设不断完善，为患者赢得了宝贵的救治时间，也为行业发展积累了宝贵经 验。不过，实践中也发现，跨省市的长途医疗转运体系仍有待完善。 院前急救网络不断完善，急救效率提高 一天傍晚，云南省急救中心调度员滕华接到求救电话：一位老人突然呼吸困难，需要紧急救治。 "老人神志是否清楚？别着急，救护车马上就到。"滕华询问病情的同时，电脑上的急救平台系统已经自 动锁定呼叫者定位，并梳理出最近的待命救护车，将任务指令发送至执行任务车辆。从接到求救电话到 派出车辆，整个过程只有1分钟。 12分钟后，救护车抵达现场，急救医生迅速进行现场处置。吸氧、测量生命体征、第一时间与送达医院 急诊科联系开通绿色通道……患者成功得到救治。 据统计，在云南昆明，主城区院前急救平均到达时间从2020年的17分钟缩短至现在的12分钟。院前急救 争分夺秒，节约下来的每分每秒都是生命的希望。 云南省急救中心通过搭建全省统一的院前急救指挥调度云平台和"120"急救专网，实现了全省急救信息 的互联互通，有效缩短急救 ...

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. specializes in the manufacturing of medical devices and consumables in the respiratory health sector, with key products including various types of sleep breathing machines and monitoring devices [1] - The company holds a total of 633 domestic patents, including 107 invention patents and 390 utility model patents, as well as 202 international patents across multiple countries [1] Financial Performance - For Q1 2025, the company reported a revenue of 265 million yuan, representing a year-on-year increase of 38.11%, and a net profit of 71.93 million yuan, up 44.11% year-on-year [2] - The company's gross profit margin stands at 49.57% [2] Market Position - As of July 4, the company's stock closed at 83.14 yuan, with a rolling price-to-earnings (PE) ratio of 41.99, while the average PE ratio in the medical device industry is 51.05 [1][2] - The company's total market capitalization is 7.449 billion yuan [1] Capital Flow - On July 4, the company experienced a net outflow of 3.0578 million yuan in principal funds, with a total outflow of 370,800 yuan over the past five days [1]

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. specializes in the manufacturing of medical devices and consumables in the respiratory health sector, with key products including various types of sleep breathing machines and monitoring devices [2] - The company holds a total of 633 domestic patents, including 107 invention patents, 390 utility model patents, and 136 design patents, as well as 202 international patents across multiple countries [2] Financial Performance - For the first quarter of 2025, the company reported a revenue of 265 million yuan, representing a year-on-year increase of 38.11%, and a net profit of 71.93 million yuan, up 44.11% year-on-year, with a gross profit margin of 49.57% [2] Market Position - As of June 9, the company's stock closed at 84.6 yuan, down 1.12%, with a rolling price-to-earnings (PE) ratio of 42.73 times, and a total market capitalization of 7.58 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 50.64 times and a median of 37.05 times, Ruimait ranks 85th in terms of PE ratio [1][3] Shareholding Structure - As of the first quarter of 2025, a total of 14 institutions held shares in Ruimait, including 6 funds, 5 other institutions, 2 brokerages, and 1 social security fund, with a total holding of 26.92 million shares valued at 2.172 billion yuan [1]